Merck & Co., Inc. Derivative Liability, Fair Value, Amount Not Offset Against Collateral
Merck & Co., Inc. (MRK) had Derivative Liability, Fair Value, Amount Not Offset Against Collateral of $6.00 million as of 2014-12-31, per its 10-K filed 2015-02-27.
Discontinued › Notes › Offsetting › Offsetting Derivative Liabilities › Derivative Liability, Subject to Master Netting Arrangement, after Offset and Deduction › Derivative Liability, Subject to Master Netting Arrangement, before Offset of Collateral
us-gaap:DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral · last filed 2015-02-27
- 2014-12-31: Derivative Liability, Fair Value, Amount Not Offset Against Collateral $6.00M.
- 2013-12-31: Derivative Liability, Fair Value, Amount Not Offset Against Collateral $37.00M.
- 2013-09-30: Derivative Liability, Fair Value, Amount Not Offset Against Collateral $5.00M.
- 2012-12-31: Derivative Liability, Fair Value, Amount Not Offset Against Collateral $34.00M.
| Period end | Derivative Liability, Fair Value, Amount Not Offset Against Collateral |
|---|---|
| 2014-12-31 | $6.00M 10-K · filed 2015-02-27 |
| 2013-12-31 | $37.00M 10-K · filed 2015-02-27 |
| 2013-09-30 | $5.00M 10-Q · filed 2013-11-07 |
| 2012-12-31 | $34.00M 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |